Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples
The subjects were taking 176 to 880 μg/d fluticasone (or equivalent) with or without β-agonists, a leukotriene receptor antagonist, or theophylline; used 2 or fewer steroid bursts in the previous year and none in the previous 3 months with less than 30 days of oral steroids in the previous 12 mont...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2010-05, Vol.125 (5), p.1161-1163.e4 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1163.e4 |
|---|---|
| container_issue | 5 |
| container_start_page | 1161 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 125 |
| creator | Al-Samri, Mohammed T., MD Benedetti, Andrea, PhD Préfontaine, David, MSc Olivenstein, Ron, MD Lemière, Catherine, MD, MSc Nair, Parameswaran, MD, PhD Martin, James G., MD, DSc Hamid, Qutayba, MD, PhD |
| description | The subjects were taking 176 to 880 μg/d fluticasone (or equivalent) with or without β-agonists, a leukotriene receptor antagonist, or theophylline; used 2 or fewer steroid bursts in the previous year and none in the previous 3 months with less than 30 days of oral steroids in the previous 12 months; had an FEV1 of 70% or greater of predicted value and 90% or greater of personal best in previous 2 years; and had 1 or more unscheduled visits for asthma in the previous 12 months.  Severe asthma[low *] (n = 37) Moderate asthma[low *] (n = 24) P value Age (y) 47.6 ± 11.76 51.6 ± 10.2 NS Sex (M/F) 21/16 14/10 NS FEV1 (% predicted)[dagger] 66.6 ± 21.9 85.0 ± 12.2 .0003 Prebronchodilator FEV1/FVC ratio 65.7 ± 11.9 73.1 ± 5.5 .0058 BMI (kg/m2) 28.2 ± 6.1 27.2 ± 6.3 NS Subjects with atopy[double dagger] 31 (84%) 21 (88%) NS Dose of inhaled corticosteroid (μg/d)[low *] 1,275 ± 324 618 ± 325 |
| doi_str_mv | 10.1016/j.jaci.2010.02.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754869853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674910002848</els_id><sourcerecordid>3389957161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-3b92b05324fbab32b82131989517fafdb726496d23aae718f892f8f94a856bc23</originalsourceid><addsrcrecordid>eNqFksuKFTEQhhtRnOPoC7iQgIirPubSl0REGAZvMODCyzak04mTtm-TSh_oZ_ClreYcHZiFbhJS-f5Kqv7KsqeM7hll1atu3xkb9pxigPI9peW9bMeoqvNK8vJ-tqNUsbyqC3WWPQLoKJ6FVA-zM06F4oWsdtmv7yYG04Q-pJVMnsC8pGUgYfS9GQaTprgS6_oeMEQMpGuMBUtmXN2YgERnXTiE8QexU8SbCZKLU2hJunbRzOtrckHmOMHsbAoHRyAt7UoW2BTD0qcw9xg0A27wOHvgTQ_uyWk_z769f_f18mN-9fnDp8uLq9yWRZFy0Sje0FLwwjemEbyRnAmmpCpZ7Y1vm5pXhapaLoxxNZNeKu6lV4WRZdVYLs6zl8e8-LGbxUHSQ4CtSDO6aQFdl9gaJUvxf1IIQbH_Esnnd8huWuKIZWhWlpQpptRG8SNlsSUQnddzDIOJq2ZUb57qTm-e6s1TTblGT1H07JR6aQbX_pX8MRGBFyfAgDW9j2a0AW45LrlQRY3cmyPnsLmH4KIGiy5a1wa0Mel2Cv_-x9s7ctuHMeCLP93q4LZeDSjQX7bp24aP4dxxWUjxGxeY1pA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1550191998</pqid></control><display><type>article</type><title>Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Al-Samri, Mohammed T., MD ; Benedetti, Andrea, PhD ; Préfontaine, David, MSc ; Olivenstein, Ron, MD ; Lemière, Catherine, MD, MSc ; Nair, Parameswaran, MD, PhD ; Martin, James G., MD, DSc ; Hamid, Qutayba, MD, PhD</creator><creatorcontrib>Al-Samri, Mohammed T., MD ; Benedetti, Andrea, PhD ; Préfontaine, David, MSc ; Olivenstein, Ron, MD ; Lemière, Catherine, MD, MSc ; Nair, Parameswaran, MD, PhD ; Martin, James G., MD, DSc ; Hamid, Qutayba, MD, PhD</creatorcontrib><description>The subjects were taking 176 to 880 μg/d fluticasone (or equivalent) with or without β-agonists, a leukotriene receptor antagonist, or theophylline; used 2 or fewer steroid bursts in the previous year and none in the previous 3 months with less than 30 days of oral steroids in the previous 12 months; had an FEV1 of 70% or greater of predicted value and 90% or greater of personal best in previous 2 years; and had 1 or more unscheduled visits for asthma in the previous 12 months.  Severe asthma[low *] (n = 37) Moderate asthma[low *] (n = 24) P value Age (y) 47.6 ± 11.76 51.6 ± 10.2 NS Sex (M/F) 21/16 14/10 NS FEV1 (% predicted)[dagger] 66.6 ± 21.9 85.0 ± 12.2 .0003 Prebronchodilator FEV1/FVC ratio 65.7 ± 11.9 73.1 ± 5.5 .0058 BMI (kg/m2) 28.2 ± 6.1 27.2 ± 6.3 NS Subjects with atopy[double dagger] 31 (84%) 21 (88%) NS Dose of inhaled corticosteroid (μg/d)[low *] 1,275 ± 324 618 ± 325 <.0001 Asthma exacerbation per subject per visit in the previous year 0.1 ± 0.1 0.03 ± 0.07 .007 Exsmokers 14 (38%) 7 (29%) NS Symptom score 1.8 ± 1.0 1.0 ± 0.6 .001 Subjects taking oral steroids 25 (68%) 3 (13%) <.0001 Subjects taking long-acting β2-agonists[dagger] 36 (97%) 17 (71%) .0036 Table I Clinical characteristics Values are presented as means ± SDs or numbers.BMI, Body mass index; F, female; FVC, forced vital capacity; M, male; NS, not significant.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2010.02.005</identifier><identifier>PMID: 20392486</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Administration, Inhalation ; Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - therapeutic use ; Adult ; Allergy and Immunology ; Androstadienes - administration & dosage ; Androstadienes - therapeutic use ; Animals ; Asthma ; Asthma - drug therapy ; Asthma - immunology ; Asthma - physiopathology ; Biological and medical sciences ; Body mass index ; Chronic obstructive pulmonary disease, asthma ; Eosinophils - cytology ; Eosinophils - immunology ; Female ; Fluticasone ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunopathology ; Inflammation - drug therapy ; Inflammation - immunology ; Inflammation - physiopathology ; Male ; Medical sciences ; Middle Aged ; Neutrophils - cytology ; Neutrophils - immunology ; Patients ; Pneumology ; Prospective Studies ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Sputum - cytology ; Sputum - drug effects ; Sputum - immunology ; Treatment Outcome ; Values</subject><ispartof>Journal of allergy and clinical immunology, 2010-05, Vol.125 (5), p.1161-1163.e4</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2010 American Academy of Allergy, Asthma & Immunology</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-3b92b05324fbab32b82131989517fafdb726496d23aae718f892f8f94a856bc23</citedby><cites>FETCH-LOGICAL-c544t-3b92b05324fbab32b82131989517fafdb726496d23aae718f892f8f94a856bc23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2010.02.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22823947$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20392486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Samri, Mohammed T., MD</creatorcontrib><creatorcontrib>Benedetti, Andrea, PhD</creatorcontrib><creatorcontrib>Préfontaine, David, MSc</creatorcontrib><creatorcontrib>Olivenstein, Ron, MD</creatorcontrib><creatorcontrib>Lemière, Catherine, MD, MSc</creatorcontrib><creatorcontrib>Nair, Parameswaran, MD, PhD</creatorcontrib><creatorcontrib>Martin, James G., MD, DSc</creatorcontrib><creatorcontrib>Hamid, Qutayba, MD, PhD</creatorcontrib><title>Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>The subjects were taking 176 to 880 μg/d fluticasone (or equivalent) with or without β-agonists, a leukotriene receptor antagonist, or theophylline; used 2 or fewer steroid bursts in the previous year and none in the previous 3 months with less than 30 days of oral steroids in the previous 12 months; had an FEV1 of 70% or greater of predicted value and 90% or greater of personal best in previous 2 years; and had 1 or more unscheduled visits for asthma in the previous 12 months.  Severe asthma[low *] (n = 37) Moderate asthma[low *] (n = 24) P value Age (y) 47.6 ± 11.76 51.6 ± 10.2 NS Sex (M/F) 21/16 14/10 NS FEV1 (% predicted)[dagger] 66.6 ± 21.9 85.0 ± 12.2 .0003 Prebronchodilator FEV1/FVC ratio 65.7 ± 11.9 73.1 ± 5.5 .0058 BMI (kg/m2) 28.2 ± 6.1 27.2 ± 6.3 NS Subjects with atopy[double dagger] 31 (84%) 21 (88%) NS Dose of inhaled corticosteroid (μg/d)[low *] 1,275 ± 324 618 ± 325 <.0001 Asthma exacerbation per subject per visit in the previous year 0.1 ± 0.1 0.03 ± 0.07 .007 Exsmokers 14 (38%) 7 (29%) NS Symptom score 1.8 ± 1.0 1.0 ± 0.6 .001 Subjects taking oral steroids 25 (68%) 3 (13%) <.0001 Subjects taking long-acting β2-agonists[dagger] 36 (97%) 17 (71%) .0036 Table I Clinical characteristics Values are presented as means ± SDs or numbers.BMI, Body mass index; F, female; FVC, forced vital capacity; M, male; NS, not significant.</description><subject>Administration, Inhalation</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Androstadienes - administration & dosage</subject><subject>Androstadienes - therapeutic use</subject><subject>Animals</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - immunology</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Body mass index</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Eosinophils - cytology</subject><subject>Eosinophils - immunology</subject><subject>Female</subject><subject>Fluticasone</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - immunology</subject><subject>Inflammation - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neutrophils - cytology</subject><subject>Neutrophils - immunology</subject><subject>Patients</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Sputum - cytology</subject><subject>Sputum - drug effects</subject><subject>Sputum - immunology</subject><subject>Treatment Outcome</subject><subject>Values</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksuKFTEQhhtRnOPoC7iQgIirPubSl0REGAZvMODCyzak04mTtm-TSh_oZ_ClreYcHZiFbhJS-f5Kqv7KsqeM7hll1atu3xkb9pxigPI9peW9bMeoqvNK8vJ-tqNUsbyqC3WWPQLoKJ6FVA-zM06F4oWsdtmv7yYG04Q-pJVMnsC8pGUgYfS9GQaTprgS6_oeMEQMpGuMBUtmXN2YgERnXTiE8QexU8SbCZKLU2hJunbRzOtrckHmOMHsbAoHRyAt7UoW2BTD0qcw9xg0A27wOHvgTQ_uyWk_z769f_f18mN-9fnDp8uLq9yWRZFy0Sje0FLwwjemEbyRnAmmpCpZ7Y1vm5pXhapaLoxxNZNeKu6lV4WRZdVYLs6zl8e8-LGbxUHSQ4CtSDO6aQFdl9gaJUvxf1IIQbH_Esnnd8huWuKIZWhWlpQpptRG8SNlsSUQnddzDIOJq2ZUb57qTm-e6s1TTblGT1H07JR6aQbX_pX8MRGBFyfAgDW9j2a0AW45LrlQRY3cmyPnsLmH4KIGiy5a1wa0Mel2Cv_-x9s7ctuHMeCLP93q4LZeDSjQX7bp24aP4dxxWUjxGxeY1pA</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Al-Samri, Mohammed T., MD</creator><creator>Benedetti, Andrea, PhD</creator><creator>Préfontaine, David, MSc</creator><creator>Olivenstein, Ron, MD</creator><creator>Lemière, Catherine, MD, MSc</creator><creator>Nair, Parameswaran, MD, PhD</creator><creator>Martin, James G., MD, DSc</creator><creator>Hamid, Qutayba, MD, PhD</creator><general>Mosby, Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples</title><author>Al-Samri, Mohammed T., MD ; Benedetti, Andrea, PhD ; Préfontaine, David, MSc ; Olivenstein, Ron, MD ; Lemière, Catherine, MD, MSc ; Nair, Parameswaran, MD, PhD ; Martin, James G., MD, DSc ; Hamid, Qutayba, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-3b92b05324fbab32b82131989517fafdb726496d23aae718f892f8f94a856bc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Inhalation</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Androstadienes - administration & dosage</topic><topic>Androstadienes - therapeutic use</topic><topic>Animals</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - immunology</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Body mass index</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Eosinophils - cytology</topic><topic>Eosinophils - immunology</topic><topic>Female</topic><topic>Fluticasone</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - immunology</topic><topic>Inflammation - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neutrophils - cytology</topic><topic>Neutrophils - immunology</topic><topic>Patients</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Sputum - cytology</topic><topic>Sputum - drug effects</topic><topic>Sputum - immunology</topic><topic>Treatment Outcome</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Samri, Mohammed T., MD</creatorcontrib><creatorcontrib>Benedetti, Andrea, PhD</creatorcontrib><creatorcontrib>Préfontaine, David, MSc</creatorcontrib><creatorcontrib>Olivenstein, Ron, MD</creatorcontrib><creatorcontrib>Lemière, Catherine, MD, MSc</creatorcontrib><creatorcontrib>Nair, Parameswaran, MD, PhD</creatorcontrib><creatorcontrib>Martin, James G., MD, DSc</creatorcontrib><creatorcontrib>Hamid, Qutayba, MD, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Samri, Mohammed T., MD</au><au>Benedetti, Andrea, PhD</au><au>Préfontaine, David, MSc</au><au>Olivenstein, Ron, MD</au><au>Lemière, Catherine, MD, MSc</au><au>Nair, Parameswaran, MD, PhD</au><au>Martin, James G., MD, DSc</au><au>Hamid, Qutayba, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>125</volume><issue>5</issue><spage>1161</spage><epage>1163.e4</epage><pages>1161-1163.e4</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>The subjects were taking 176 to 880 μg/d fluticasone (or equivalent) with or without β-agonists, a leukotriene receptor antagonist, or theophylline; used 2 or fewer steroid bursts in the previous year and none in the previous 3 months with less than 30 days of oral steroids in the previous 12 months; had an FEV1 of 70% or greater of predicted value and 90% or greater of personal best in previous 2 years; and had 1 or more unscheduled visits for asthma in the previous 12 months.  Severe asthma[low *] (n = 37) Moderate asthma[low *] (n = 24) P value Age (y) 47.6 ± 11.76 51.6 ± 10.2 NS Sex (M/F) 21/16 14/10 NS FEV1 (% predicted)[dagger] 66.6 ± 21.9 85.0 ± 12.2 .0003 Prebronchodilator FEV1/FVC ratio 65.7 ± 11.9 73.1 ± 5.5 .0058 BMI (kg/m2) 28.2 ± 6.1 27.2 ± 6.3 NS Subjects with atopy[double dagger] 31 (84%) 21 (88%) NS Dose of inhaled corticosteroid (μg/d)[low *] 1,275 ± 324 618 ± 325 <.0001 Asthma exacerbation per subject per visit in the previous year 0.1 ± 0.1 0.03 ± 0.07 .007 Exsmokers 14 (38%) 7 (29%) NS Symptom score 1.8 ± 1.0 1.0 ± 0.6 .001 Subjects taking oral steroids 25 (68%) 3 (13%) <.0001 Subjects taking long-acting β2-agonists[dagger] 36 (97%) 17 (71%) .0036 Table I Clinical characteristics Values are presented as means ± SDs or numbers.BMI, Body mass index; F, female; FVC, forced vital capacity; M, male; NS, not significant.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>20392486</pmid><doi>10.1016/j.jaci.2010.02.005</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2010-05, Vol.125 (5), p.1161-1163.e4 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754869853 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Inhalation Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use Adult Allergy and Immunology Androstadienes - administration & dosage Androstadienes - therapeutic use Animals Asthma Asthma - drug therapy Asthma - immunology Asthma - physiopathology Biological and medical sciences Body mass index Chronic obstructive pulmonary disease, asthma Eosinophils - cytology Eosinophils - immunology Female Fluticasone Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunopathology Inflammation - drug therapy Inflammation - immunology Inflammation - physiopathology Male Medical sciences Middle Aged Neutrophils - cytology Neutrophils - immunology Patients Pneumology Prospective Studies Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Sputum - cytology Sputum - drug effects Sputum - immunology Treatment Outcome Values |
| title | Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A33%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Variability%20of%20sputum%20inflammatory%20cells%20in%20asthmatic%20patients%20receiving%20corticosteroid%20therapy:%20A%20prospective%20study%20using%20multiple%20samples&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Al-Samri,%20Mohammed%20T.,%20MD&rft.date=2010-05-01&rft.volume=125&rft.issue=5&rft.spage=1161&rft.epage=1163.e4&rft.pages=1161-1163.e4&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2010.02.005&rft_dat=%3Cproquest_cross%3E3389957161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1550191998&rft_id=info:pmid/20392486&rft_els_id=1_s2_0_S0091674910002848&rfr_iscdi=true |